title: Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS.
abstract: OBJECTIVE
  B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS) has been increasingly reported in Asia and is regarded as a variant of intravascular lymphomatosis (IVL). Recently CD5 was reported to be expressed in some cases of diffuse large cell lymphoma and IVL. We therefore examined the expression of CD5 on lymphoma cells in B-LAHS and compared the clinical and laboratory data between CD5+ and CD5- B-LAHS.
  
  
  METHODS
  The expression of CD5 on lymphoma cells was examined using flow cytometry and immunohistochemical analysis of paraffin sections. The clinical records were reviewed to characterize clinical features.
  
  
  METHODS
  Twelve patients with B-LAHS; ten men and two women, age ranging from 41 to 82 years (median, 63.5 years) were included in this study.
  
  
  RESULTS
  B-LAHS is characterized by fever and hepatosplenomegaly without lymphadenopathy at the initial presentation. Histological examination showed hemophagocytosis and infiltration of lymphoma cells in the bone marrow, and in some cases intravascular proliferation of lymphoid cells characteristic of IVL. All patients showed increased levels of lactate dehydrogenase, C-reactive protein, ferritin and soluble interleukin-2 receptor. In eight of the twelve patients, lymphoma cells were positive for CD5. But no differences were observed in the clinical or laboratory findings between CD5+ B-LAHS and CD5- B-LAHS.
  
  
  CONCLUSIONS
  No clinical differences were observed between CD5+ B-LAHS and CD5- B-LAHS. Further studies are required to elucidate the differences in pathogenesis between these two subgroups of B-LAHS.
authors.affiliation: Second Department of Medicine, Kyoto Prefectural University of Medicine.
authors.forename: C
authors.initials: C
authors.lastname: Shimazaki
authors.forename: T
authors.initials: T
authors.lastname: Inaba
authors.forename: A
authors.initials: A
authors.lastname: Okano
authors.forename: M
authors.initials: M
authors.lastname: Hatsuse
authors.forename: R
authors.initials: R
authors.lastname: Takahashi
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: Y
authors.initials: Y
authors.lastname: Sudo
authors.forename: E
authors.initials: E
authors.lastname: Ashihara
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: S
authors.initials: S
authors.lastname: Murakami
authors.forename: K
authors.initials: K
authors.lastname: Saigo
authors.forename: H
authors.initials: H
authors.lastname: Tsuda
authors.forename: N
authors.initials: N
authors.lastname: Fujita
authors.forename: M
authors.initials: M
authors.lastname: Nakagawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018956:CD5 Antigens / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry; D015616:Histiocytosis, Non-Langerhans-Cell / Q000276:immunology* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000150:complications* / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D018956:CD5 Antigens